CGEM

Cullinan Therapeutics, Inc.

Phase 1 Confirmed

CLN-049

AML

Countdown

177days

Phase 1 readout · ~ Dec 31, 2026 estimated

What's at stake Phase 1 trial results for CLN-049 in AML are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 15h ago

“Dose level expansion continues in order to determine the recommended Phase 2 dose (RP2D) by Q4 2026 for a potential single-arm pivotal registrational trial.”

Add to calendar Post on X Reddit

Provenance